This unsung hero has been a pivotal invention in the history of real-time PCR. It has been the key constitute of all our probes and is responsible for the high accuracy and sensitivity of all our assays. Further, the MGB-oligonucleotide complexes or MGB Probe has been a popular molecule of choice in the realm of molecular diagnostics.

The MGB molecule reversibly binds to the minor groove of double-stranded DNA in a stable configuration due to hydrophobic and Van Der Waals interactions. When linked to an oligonucleotide, MGB allows the formation of highly stable DNA duplex. The resulting highly stable complexes inhibit strand separation and prevent DNA processing and packaging functions. The increased stability of the DNA template / MGB-oligonucleotide duplex offers many advantages. These include:

• Allows design of shorter oligonucleotide probes: improving the mismatch discrimination efficiency and reducing the possibility for the formation of secondary structure and dimers among primer and probes
• Synergistic quenching with Eclipse Dark Quencher®: further decreasing background fluorescence and improving sensitivity with ELITechGroup MDx LLC best in class quencher molecule.
• Bringing fluorophore closer to quencher: decreasing background fluorescence and improving sensitivity
• Equalizing binding stability of A-T and G-C region: stabilizing the A-T-rich regions, reduces the influence of DNA sequence on the probe melting temperature (Tm).
• Opening doors to new assay designs: short target sequences, challenging A-T rich regions, polymorphic regions, and detection of mismatched variants

The impact of MGB-Probes extends across various fields, from infectious diseases to the detection of cancer markers. As a scientific community today, we celebrate the contribution of Mole as the foundation of chemistry. We also take the occasion to extend our gratitude and celebrate the contribution of the pioneering chemists of the ELITechGroup who laid the foundation for this groundbreaking technology.

ElitechGroup Mdx is pleased to announce that ELIVERSE will be launched in Europe in 2024.
With its introduction, ELITechGroup will have launched three molecular sample-to-result platforms in 8 years.

Read the press release here.

Turin, 22nd December 2022 – ELITechGroup has inaugurated its new headquarters in Turin, becoming one of the largest molecular biology hubs in Europe.

The inauguration was held on Friday 16th December in the presence of institutional figures, collaborators, and employees.

At the ribbon cutting, Michela Favaro – Deputy Mayor of Turin – and Roberto Meda – ELITechGroup’s Senior Vice President responsible for Molecular Diagnostics.

The company, founded 30 years ago as a spin-off of the University of Turin, has established itself in the field of molecular biology moving from a local to a multinational reality.

“We are proud to inaugurate this new headquarters – said Roberto Meda – ELITechGroup’s Senior Vice President responsible for Molecular Diagnostics – It has been possible thanks to the company’s top-level scientific expertise, managerial courage, passion, and propensity for innovation. These have been the steps behind the strategic investments, which, together with the extraordinary human and professional qualities of the women and men in our company, have enabled us to achieve exceptional results, thus becoming a reference centre for molecular biology worldwide. A larger and more innovative hub where we will be able to better experience the company, with its new and modern spaces designed for a new social networking.”

About ELITechGroup

ELITechGroup is a privately held group of worldwide manufacturers and distributors of in vitro diagnostic equipment and reagents. By bringing together IVD specialty companies that offer innovative products and solutions, ELITechGroup has become a major contributor in advancing clinical diagnostics to laboratories in the proximity market, those operating closer to the patient.

Bioperfectus launched the Monkeypox Virus Real Time PCR Kit with CE marking on May 24^th, 2022. Based on real-time PCR technology, the kit is specifically designed on the F3L gene areas of the monkeypox virus. In addition, the kit also contains a housekeeping gene (RNase P) as an internal control (IC) for specimen sampling and nucleic acid extraction.

BioPerfectus and ELITechGroup are collaborating to provide the BioPerfectus Monkeypox Virus Real Time PCR Kit exclusively for ELITe InGenius and BeGenius instruments to offer the first fully automated monkeypox diagnostic solution on the market. Both parties aim to support diagnostic capacity to fight the monkeypox outbreak.

According to the World Health Organization, real-time PCR is the preferred method for monkeypox virus surveillance given its accuracy and sensitivity. ELITechGroup is thrilled to gain Bioperfectus as a solid partner in monkeypox virus testing in Europe.

About ELITechGroup:

ELITechGroup S.p.A. is the headquarter of the Molecular Diagnostics division of ELITechGroup, which develops innovative molecular diagnostic solutions targeted for infectious diseases. By bringing together IVD specialty companies that offer innovative products and solutions, ELITechGroup manufactures and distributes diagnostic products for clinical chemistry, microbiology, hematology, and molecular biology through direct sales and a distribution network encompassing more than 100 countries. For more information, please visit www.elitechgroup.com.

About Bioperfectus:

Bioperfectus, a publicly listed company on the Shanghai Stock Exchange (SSE:688399), has been a leading molecular diagnostic solution provider specializing in infectious diseases since 2010. With headquarters in Jiangsu, and subsidiaries in Shanghai, Beijing, Xi’an, Taizhou, Hainan, and Yinchuan, Bioperfectus is a pioneer in the molecular diagnostics market with products ranging from real-time PCR kits, nucleic acid extraction systems, rapid tests, and automated laboratory devices. Young and passionate, Bioperfectus is working steadily and firmly to achieve the dream of creating a healthier future for our next generations. For more information, please visit www.bioperfectus.com.

“